Dr Gordon Sanghera
Chief Executive Officer
Gordon Sanghera was co-founder of Oxford Nanopore, together with Hagan Bayley and IP Group. He was appointed CEO in June 2005. He brings over 20 years' experience in the design, development and global launch of disruptive platform sensor technologies.
Dr Sanghera’s PhD in bioelectronics sensing was followed by a career at MediSense an Oxford spin-out that delivered a new generation glucose technology to the market. Following the acquisition of MediSense by Abbott Laboratories Dr Sanghera held both UK and US VP and Director-level positions, including VP World Wide Marketing, Research Director and Manufacturing Process Development Director. Before its acquisition by Abbott, Gordon led the R&D of Medisense Inc. where he was instrumental in the launch of several generations of blood glucose bio-electronic systems for the consumer and hospital medical markets. He has also developed and validated production processes to meet with the regulatory requirements for USA and Europe.
Gordon has a PhD in bio-electronic technology and a degree in Chemistry.
Read the article about Dr Sanghera in the Financial Times.
Dr Spike Willcocks
Chief BD Officer
After completing an MA in Chemistry and a DPhil in Biochemistry at the University of Oxford, Dr Willcocks became one of the initial members of IPGroup Plc following its landmark deal with the Chemistry Department at Oxford. Ultimately leading the Life Science team, Dr Willcocks' role encompassed all aspects of technology commercialisation, including spin-out company formation and business and corporate development, as well as private and public equity financings.
Dr Willcocks was a key player in the creation of 14 life science businesses based on technology from three universities, leading proposals for the investment of £4m in seed financing from IPGroup and holding positions of Director and Chairman for 6 portfolio companies. Working alongside the executive teams of the portfolio companies, Dr Willcocks played an integral role in out-licensing transactions, co-development deals and acquisitions. As well as supporting fundraisings for portfolio biotechnology companies, raising an aggregate of £20m, Dr Willcocks also assisted with IPGroup's own IPO in October 2003 on the LSE, raising £30m and capitalising the company at over £100m. Dr Willcocks was actively involved in the establishment of ONL whilst at IPGroup before joining full time in January 2006.
He is also a leading real tennis player, and regularly competes in international tournaments.
Chief Technology Officer
Clive Brown is CTO of Oxford Nanopore, where he leads the innovation of breakthrough technologies and product development, that are designed to enable the analysis of anything, by anyone, anywhere.
Clive has held a variety of roles in Genomics and Genetic R&D, he also played a key role in developing the Solexa NGS platform that is now the basis for Illumina’s sequencing technology.
Dr John Milton
Chief Scientific Officer
John is Chief Scientific Officer at Oxford Nanopore. On the Executive team, he has responsibility for all chemical and biological R&D activity within the company and particularly the design and delivery of the company’s nanopore-based sequencing technology. John drives the primary architectural designs of the chemical systems, building a disruptive system ready for launch into the marketplace.
John joined Oxford Nanopore from Solexa (2001–2007), where as Senior Director of R&D he designed and built the Reversible Terminator chemistry that now drives the Illumina HiSeq/MiSeq system. He built and managed a large, multi-disciplinary scientific team in areas including synthetic nucleotide chemistry, fluorescence chemistry, photochemistry, enzyme engineering, sample prep and chip surface chemistry. He also drove development of the full sequencing protocols and ultimately the scale-up and production of the sequencing reagents for commercial launch. The scientific work of John’s team was critical to the achievement of early sequence data that progressed to other major sequencing milestones and ultimately a full human genome. Solexa was sold to Illumina for $650m in 2007 after the successful placement of 12 instruments, and the Illumina systems are now considered the market leader.
Earlier in his career, following his Ph.D in Chemistry (Liverpool) and two years of post-doctoral work (Leeds), John held various scientific and management positions in medicinal chemistry firstly at GlaxoWellcome (four years) then at Xenova (four years), where he specialised in designing new chemical systems that interact with the biological machinery of genetic processing with applications as antiviral and anti-cancer therapeutics.
SVP, Corporate Development and Investment
John Schoellerman joined Oxford Nanopore in July 2019 as SVP, Corporate Development and Investment. John joined from Lazard, where he had been Managing Director and head of Medtech, leading a broad range of strategic transactions for clients in US, Europe and Asia. Previously, John worked in healthcare investment banking at J.P. Morgan in San Francisco, London and New York. John holds a B.A. from Harvard and an M.B.A. from INSEAD.
A Chartered Accountant and operations specialist, Tim was interim Finance Director at Oxford Nanopore for several months in 2009, handing over a stable and well documented finance infrastructure. He then joined Oxford Nanopore as Commercial Operations Director in 2012.
In his first five years at the company Tim was responsible for setting up and managing operations and infrastructure across the company, including leading on operations for our first product launch – the MinION Access Programme – in 2015.
As part of his Operations role, Tim selected and implemented our Enterprise Resource Planning system which has remained robust and fit for purpose throughout the company's rapid growth and development.
Tim was appointed as VP-Finance in 2017 and continues to ensure that Oxford Nanopore’s values of agility and entrepreneurialism are reflected in our corporate governance, risk control and business processes, to maximise business efficiency.
Having qualified as an accountant at Ernst & Young, Tim became Financial Controller of Celltech Group plc where he was a key member of the IPO team and managed several transactions of the Listed company. He went on to co-found Sterilox and ran the finance function before joining Clipper Ventures plc as Finance Director. Tim has also been Finance Director at British Biotech plc (Vernalis plc) as well as managing a portfolio of biotech and technology companies, including the AIM-listed Bioventix plc, before joining Oxford Nanopore.
VP, Marketing and Corporate Affairs
Zoe McDougall, VP of Corporate and Communications, joined Oxford Nanopore in 2008. As part of the leadership team, she works across corporate and commercial teams at the Company.
Zoe started her career in sales & marketing at SmithKline Beecham. She subsequently managed a range of strategic scientific and healthcare communications at the agency Porter Novelli, where clients included GSK, BMS, Pfizer and a range of other healthcare clients. During this time Zoe also worked on crisis communications around the nvCJD issue. Before joining Oxford Nanopore, Zoe was part of the IPO team and subsequently led investor relations for a UK specialty pharma company Sinclair Pharma. In 2005 she worked with a medical humanitarian organisation in Sri Lanka.
VP, General Counsel
Jordan Herman joined Oxford Nanopore in 2021 as General Counsel. Prior to this Jordan was a partner at Baker Botts L.L.P., where he was our outside counsel for over a decade. He’s long been involved in supporting our growth from a dozen people to a global company; from an idea to an industry leading technology.
Jordan leads our growing in-house legal team, and his responsibilities reflect our growth journey both corporately and commercially. His main remit is to ensure his team have the desire and ability to enable the company to grow, flourish and innovate while remaining legal, ethical and reflecting our values.
Jordon’s role includes supporting and collaborating with leadership team, overseeing the legal department, negotiating legal transactions and identifying and managing risk. He and his team are also working on strengthening internal controls, simplifying our terms and conditions and establishing processes for global monitoring and compliance.
Jordan has many years’ experience in areas including technology transfer and commercial agreements, M&A, joint ventures, licensing, and venture capital. He has worked across the life science, software, medical device and digital media industries, supporting high growth businesses in the US, Europe and around the world.
Jordan was most recently Baker Botts L.L.P., Chair of the Austin Office Corporate Department and Co-Chair of the Life Sciences group. He JD from The Ohio State University, following which he clerked for the Hon. James Rosenbaum, formerly, Chief Judge for the U.S. District Court, District of Minnesota. Jordan also has a degree in Political Economy from Washington University.
VP, Product & Programme Management
Rosemary leads the Product Management team at Oxford Nanopore Technologies, helping enable the release of novel products and improvements into the field. Rosemary has over 10 years of experience in the Life Science market covering Genomics, Proteomics and Cell Biology.
Dan leads the Applications Team at Oxford Nanopore Technologies. He is a highly experienced genomics scientist with expertise in all aspects of ‘next-generation’ sequencing. He provides scientific and strategic leadership for multi-disciplinary teams in Oxford, New York and San Francisco. The Applications group aims to bring together sample prep technologies, genomics applications and bioinformatics, to expand the utility of Oxford Nanopore Technologies’ devices and help bring the benefits of these technologies to the wider world.
Roger is responsible for all Informatics and IT provision at Oxford Nanopore. He started at Oxford Nanopore in the mists of time with a background in scalable web systems and NGS data management from 10 years spent at the Hinxton Genome Campus. Roger has at least one line of code in nearly every piece of software ever produced at Nanopore. Roger literally and figuratively wears hats of many different colours but routinely spends most of his waking hours converting coffee into code. Likes good software engineering practices, reading and walks in the park. Roger is easily distracted by shiny things and would rather be making stuff with buzzword compliant technology (and lasers).
Dr James Clarke
VP, Platform Technology
Dr James Clarke is responsible for the Research Division at Oxford Nanopore Technologies Ltd working with Clive Brown to push the boundaries of nanopore technology. Over the last ten years, his work has included: pioneering strand sequencing chemistry at Oxford Nanopore, scaling up the membrane chemistry for the MinION platform, and managing the companies' nanopore consortium of world class academics.
Stuart Reid is VP of Development at Oxford Nanopore. Stuart is responsible for the specification, performance and delivery of the company?s nanopore-based sensing products and applications into the marketplace. He joined Oxford Nanopore in 2006, with a particular interest in biophysical systems and signals analysis, following a DPhil in Physics (Bionanotechnology) from Oxford University as part of the Life Sciences Interface Doctoral Training Centre. He has been instrumental at all stages of the product development cycle, from the fundamental science and invention, through specification, implementation and optimisation to delivery into the hands of our user community.
Ant Jones is VP of Engineering at Oxford Nanopore, responsible for bringing all of Nanopore?s products from concept to production; this covers Industrial design, mechanical design, electronic design, production process and equipment development and validation. Ant has 20+ years? experience mainly with-in the medical device industry taking ideas from concept to regulatory approved commercial products. Ant joined Oxford Nanopore from Lombard Medical where he was head of design developing an AAA endovascular stent graft system which has class III medical device approval worldwide. Previous to this he has designed within: IVD, Orthopeadics, automotive and Plastics industries.
VP, Global IT, Business Systems & Digital Services
Andy is VP of Global IT, Digital & Business systems and is responsible for Information technology and infrastructure across the business, including privacy and information security. His remit also includes our online presence including the corporate website, the Nanopore Community and Store as well as other digital channels. Andy has been with Oxford Nanopore for six years, having previously held senior positions in banking, telecommunication and professional services. He is also the organisation’s data protection officer.
VP Nanopore Research
Dr. Lakmal Jayasinghe leads the biological nanopore research team at Oxford Nanopore Technologies. Lakmal joined Oxford Nanopore in 2006 after finishing his PhD in chemical biology in the University of Oxford. During his PhD in the Hagan Bayley group, Lakmal has studied different nanopores and has gained a wealth of knowledge in engineering nanopores using genetic and chemical approaches. His responsibilities at ONT include improving the readout signal of the ONT platform by upgrading its current nanopore reader and discovering and engineering new nanopores to suit various ONT applications and platforms. Lakmal also works with many academic nanopore collaborators across the world to make sure Oxford Nanopore uses the best possible nanopore reader in its platforms.
Senior Director, Sales & Market Development
Dr Louisa Ludbrook is the Senior Director, Global Sales at Oxford Nanopore Technologies, she joined ONT in late 2016 to build a commercial team to deliver the vision of disrupting the traditional life sciences genomic market. Louisa holds a B.Biomed. Sci and a PhD in molecular biology (Monash University). With eight years of lab-based research experience combined with and nine years in commercial teams within the genomics life sciences sector, Louisa is a team builder and unconventional commercial leader who blends passion for people and for technology to drive change. Previous experience at Horizon Discovery Ltd, as Head of Sales, Diagnostic Products fostered a love for dynamic start-up environments and the challenges of taking cutting edge technology at low cost to a global user group. She asks the question - where can a technology take you and how quickly can we get there?
VP, Global Services
Nirmala leads the global services team which includes Technical Serivces, Field Services and Customer Services.
Nirmala has extensive experience in developing programs to transform customer experience along with a strong academic record.
Prior to joining Oxford Nanopore, Nirmala worked for General Electric where she held commercial and customer experience roles within the healthcare business.
VP, Global Human Resources
Sarah is the VP of Global Human Resources at ONT. She started consulting for ONT in 2011 before joining full time in 2013 as our first HR hire. Her initial remit was to support the executive team on critical long-term leadership recruitment, culture creation and infrastructure development around policy, process, and communication.
From day one, Sarah’s objective has been to recruit, retain and develop the best person for each role, wherever they are in the world. To this end, Sarah was instrumental in collaborating with our executive team to develop a culture imbued with our core values. Since then, we have embedded collaboration, fostered flexible working, and continue to prioritise physical and mental health, wellbeing, healthy communication and respect, all within a reward ethos.
ONT teams around the world represent a diverse and inclusive variety of people, all empowered to be responsible for their own time and delivery thanks to technology, a coaching framework, training, and accessible resources.
Alongside continually embedding our culture, talent acquisition and development, Sarah and her team have developed policies and processes which have supported ONT’s strategic transition. Once an early-stage R and D start up, ONT is now a global commercial business with the vision and technology to impact everyone and everything.
Since she completed her Business Apprenticeship in 1996, Sarah’s had national and global roles in the automotive, medical device and biotech industries, including playing an instrumental role in designing and implementing ADC’s transformation programme.
Sarah is a Chartered Member of the CIPD and holds a BA Honours Degree in Business Studies and Human Resource Management and a Post Graduate Diploma in Human Resource Management.
VP, Commercial Operations
Rich has responsibility for comprehensive operational support of Oxford Nanopore commercial units including Customer Solutions, Technical Support, Field Marketing and Corporate Expansion – including Key Customer relationship management and Channel Partners. Rich joined Oxford Nanopore from Illumina as Vice President and General Manager of Illumina – leading their EMEA Region to three years of 25% compound annual growth and to Global Region of the Year in two out of three years. Immediately prior to joining Illumina, Rich gained 12 years of experience helping commercial & research customers successfully integrate and deploy enterprise scale software solutions in both research and quality/regulated environments as Vice President & General Manager EMEA of Dassault Systèmes Biovia business unit. He holds a degree in Biochemistry with Cell and Molecular Biology from the University of Birmingham.
Emma joins at a time when the potential clinical applications of nanopore sequencing are rapidly expanding. Her experience in medical and clinical affairs will support our ambitions for growth in healthcare applications over the coming years. Emma will work closely with the clinical market development team to accelerate the introduction and scale up of a range of clinical applications. In addition, Emma will work closely with DHSC and NHS colleagues with the goal of leveraging our LamPORE diagnostic platform for COVID 19 to add new clinical assays.
Until November this year, Emma was Director of Testing Supplies and Innovation at NHS Test and Trace. Prior to this, Emma was CEO of a health care company focussed on improving efficiency across elective care pathways in the NHS. Emma brings international healthcare experience from the US where she worked for a large payer based in Massachusetts and was previously a Commonwealth Fund Harkness Fellow in Healthcare Policy and Practice at Harvard University.
Head of IP
Martyn is a highly experienced patent attorney having worked mostly for US startup companies in medical diagnostic field. He is Head of IP at ONT. Martyn’s technical background is in academic Chemistry/Electrochemistry BSc/Msc, and he has additional R&D Bioelectrochemistry experience
Phil is an experienced senior executive having held FD positions within large UK support services companies and also smaller private equity backed technology companies. He is skilled in managing finance teams, structuring deals, business integrations and organisational transformations.
Senior Director, Production
Rhod has 19 years’ experience in micro electromechanical systems (MEMS) and nanotechnology. He has held leadership roles in material science research, product development, technology transfer, manufacturing and performance management. He has delivered solutions to a broad range of customers including UK MoD, DSTL, DoD, DARPA and commercial groups.
As Senior Director of Continuous Improvement, Jerry is responsible for all aspects of Manufacturing. He has been with the company for over four years. Jeremy has over 35 years of Manufacturing experience. The Last 25 years working within the Medical Device and Nutritional Products industry and the last seven year prior to joining ONT working as a Master Black Belt supporting the deployment of Lean Six Sigma continuous improvement methodologies in Europe.
Senior Director, Global Supply Chain
As the Global Supply Chain Director for Oxford Nanopore Technologies, Al heads up the team that manage from incoming supply of materials and services, to storage of inventory, planning of production and distribution of finished goods. He has over 25 years of experience in manufacturing operations with a solid track record in leading and improving supply chains across various industries. Alvaro will be able to provide insight into ONT’s supply chain operations.
Company Secretary and Legal Director
Hannah is ONT’s Legal Director and Company Secretary. She joined ONT in 2020, having followed our journey for several years, and was attracted by our exciting, disruptive technology and the opportunity to work for a world-changing business.
Hannah specialises in corporate law and advises ONT on a range of matters including corporate transactions, corporate governance, compliance and commercial matters.
As part of an expanding legal team, Hannah is collaborating with her legal colleagues around the world to further establish the legal team as an innovative and pragmatic partner within the business.
Hannah joined ONT from FTSE 250 intellectual property commercialisation company IP Group plc, where she provided legal services to the group and its portfolio of companies. Hannah was also company secretary for AIM-listed AI company Mirriad Advertising plc.
Hannah trained and qualified at US law firm Orrick, Herrington & Sutcliffe, where she specialised in venture capital and M&A transactions with a focus on the technology sector.
VP, Strategic Programmes
Chris will be instrumental in helping us forge new programmes, ventures and entities from exciting projects, particularly in markets beyond the Life Science research tools sector. As an easy starter (!), Chris is picking up the overall co- ordination of all of the activities going into the formation of our new subsidiary, Oxford Nanopore Diagnostics Ltd, with LamPORE COVID-19 as its first product. Many of us have known Chris for a while, as he joins us from Sharp Corp, where he led the setup of Sharp Life Sciences.